These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 36335645)

  • 1. Myosin Inhibition and Left Ventricular Diastolic Function in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Insights From the VALOR-HCM Study.
    Cremer PC; Geske JB; Owens A; Jaber WA; Harb SC; Saberi S; Wang A; Sherrid M; Naidu SS; Schaff H; Smedira NG; Wang Q; Wolski K; Lampl KL; Sehnert AJ; Nissen SE; Desai MY
    Circ Cardiovasc Imaging; 2022 Dec; 15(12):e014986. PubMed ID: 36335645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks.
    Desai MY; Owens A; Geske JB; Wolski K; Saberi S; Wang A; Sherrid M; Cremer PC; Naidu SS; Smedira NG; Schaff H; McErlean E; Sewell C; Balasubramanyam A; Lampl K; Sehnert AJ; Nissen SE
    Circulation; 2023 Mar; 147(11):850-863. PubMed ID: 36335531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serial Changes in Ventricular Strain in Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Insights From the VALOR-HCM Trial.
    Desai MY; Okushi Y; Gaballa A; Wang Q; Geske JB; Owens AT; Saberi S; Wang A; Cremer PC; Sherrid M; Lakdawala NK; Tower-Rader A; Fermin D; Naidu SS; Lampl KL; Sehnert AJ; Nissen SE; Popovic ZB;
    Circ Cardiovasc Imaging; 2024 Sep; 17(9):e017185. PubMed ID: 39221824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR-HCM Randomized Clinical Trial.
    Desai MY; Owens A; Wolski K; Geske JB; Saberi S; Wang A; Sherrid M; Cremer PC; Lakdawala NK; Tower-Rader A; Fermin D; Naidu SS; Smedira NG; Schaff H; McErlean E; Sewell C; Mudarris L; Gong Z; Lampl K; Sehnert AJ; Nissen SE
    JAMA Cardiol; 2023 Oct; 8(10):968-977. PubMed ID: 37639243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy.
    Hegde SM; Lester SJ; Solomon SD; Michels M; Elliott PM; Nagueh SF; Choudhury L; Zemanek D; Zwas DR; Jacoby D; Wang A; Ho CY; Li W; Sehnert AJ; Olivotto I; Abraham TP
    J Am Coll Cardiol; 2021 Dec; 78(25):2518-2532. PubMed ID: 34915982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study Design and Rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy.
    Ho CY; Olivotto I; Jacoby D; Lester SJ; Roe M; Wang A; Waldman CB; Zhang D; Sehnert AJ; Heitner SB
    Circ Heart Fail; 2020 Jun; 13(6):e006853. PubMed ID: 32498620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Mavacamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM.
    Cresci S; Bach RG; Saberi S; Owens AT; Spertus JA; Hegde SM; Lakdawala NK; Nilles EK; Wojdyla DM; Sehnert AJ; Wang A
    Circulation; 2024 Feb; 149(7):498-509. PubMed ID: 37961906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy.
    Desai MY; Wolski K; Owens A; Naidu SS; Geske JB; Smedira NG; Schaff H; Lampl K; McErlean E; Sewell C; Zhang D; Edelberg JM; Sehnert AJ; Nissen SE
    Am Heart J; 2021 Sep; 239():80-89. PubMed ID: 34038706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mavacamten-Associated Temporal Changes in Left Atrial Function in Obstructive HCM: Insights From the VALOR-HCM Trial.
    Desai MY; Okushi Y; Wolski K; Geske JB; Owens A; Saberi S; Wang A; Cremer PC; Sherrid M; Lakdawala NK; Tower-Rader A; Fermin D; Naidu SS; Lampl KL; Sehnert AJ; Nissen SE; Popovic ZB;
    JACC Cardiovasc Imaging; 2024 Sep; ():. PubMed ID: 39254622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Olivotto I; Oreziak A; Barriales-Villa R; Abraham TP; Masri A; Garcia-Pavia P; Saberi S; Lakdawala NK; Wheeler MT; Owens A; Kubanek M; Wojakowski W; Jensen MK; Gimeno-Blanes J; Afshar K; Myers J; Hegde SM; Solomon SD; Sehnert AJ; Zhang D; Li W; Bhattacharya M; Edelberg JM; Waldman CB; Lester SJ; Wang A; Ho CY; Jacoby D;
    Lancet; 2020 Sep; 396(10253):759-769. PubMed ID: 32871100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy.
    Desai MY; Owens A; Geske JB; Wolski K; Naidu SS; Smedira NG; Cremer PC; Schaff H; McErlean E; Sewell C; Li W; Sterling L; Lampl K; Edelberg JM; Sehnert AJ; Nissen SE
    J Am Coll Cardiol; 2022 Jul; 80(2):95-108. PubMed ID: 35798455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
    Spertus JA; Fine JT; Elliott P; Ho CY; Olivotto I; Saberi S; Li W; Dolan C; Reaney M; Sehnert AJ; Jacoby D
    Lancet; 2021 Jun; 397(10293):2467-2475. PubMed ID: 34004177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Safety and Efficacy of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results of the PIONEER-OLE Study.
    Masri A; Lester SJ; Stendahl JC; Hegde SM; Sehnert AJ; Balaratnam G; Shah A; Fox S; Wang A
    J Am Heart Assoc; 2024 Apr; 13(8):e030607. PubMed ID: 38591260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy.
    Ho CY; Mealiffe ME; Bach RG; Bhattacharya M; Choudhury L; Edelberg JM; Hegde SM; Jacoby D; Lakdawala NK; Lester SJ; Ma Y; Marian AJ; Nagueh SF; Owens A; Rader F; Saberi S; Sehnert AJ; Sherrid MV; Solomon SD; Wang A; Wever-Pinzon O; Wong TC; Heitner SB
    J Am Coll Cardiol; 2020 Jun; 75(21):2649-2660. PubMed ID: 32466879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mavacamten for Obstructive Hypertrophic Cardiomyopathy With or Without Hypertension: Post-Hoc Analysis of the EXPLORER-HCM Trial.
    Wang A; Spertus JA; Wojdyla DM; Abraham TP; Nilles EK; Owens AT; Saberi S; Cresci S; Sehnert A; Lakdawala NK
    JACC Heart Fail; 2024 Mar; 12(3):567-579. PubMed ID: 37855754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mavacamten: A Novel Agent for Hypertrophic Cardiomyopathy.
    Chase Cole J; Benvie SF; DeLosSantos M
    Clin Ther; 2024 Apr; 46(4):368-373. PubMed ID: 38508915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review and meta-analysis of the efficacy and safety of Mavacamten therapy in international cohort of 524 patients with hypertrophic cardiomyopathy.
    Yacoub MS; El-Nakhal T; Hasabo EA; Shehata N; Wilson K; Ismail KH; Bakr MS; Mohsen M; Mohamed A; Abdelazim E; Ali HT; Soliman Z; Sayed A; Abdelsayed K; Caliskan K; Soliman O
    Heart Fail Rev; 2024 Mar; 29(2):479-496. PubMed ID: 38112937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evaluation of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults.
    Dong T; Nissen S; Ospina S; Desai MY
    Expert Rev Cardiovasc Ther; 2023 Jan; 21(1):5-13. PubMed ID: 36522857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Mavacamten in the Treatment of Hypertrophic Cardiomyopathy: A Systematic Review.
    Bishev D; Fabara S; Loseke I; Alok A; Al-Ani H; Bazikian Y
    Heart Lung Circ; 2023 Sep; 32(9):1049-1056. PubMed ID: 37453852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: The EXPLORER-CN Randomized Clinical Trial.
    Tian Z; Li L; Li X; Wang J; Zhang Q; Li Z; Peng D; Yang P; Ma W; Wang F; Jin W; Cheng X; Sun J; Fu Y; Lyu C; Zhang S
    JAMA Cardiol; 2023 Oct; 8(10):957-965. PubMed ID: 37639259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.